Category Archives: HIV care & treatment

AIDS2016: No HIV transmission events from condomless sex between mixed-HIV-status couples

logo_aids2016_sm

The European PARTNER study is now the second large HIV study to determine that full viral suppression due to antiretroviral therapy renders an HIV-positive person nearly completely uninfectious to their HIV-negative sex partners. The study was published in JAMA prior to the AIDS 2016 conference in…Read More

AIDS2016: Switching to single pill regimen controls HIV as well as other standard treatment

logo_aids2016_sm

New data show equal control of HIV levels when switching from a standard multi-pill regimen to the single tablet regimen of Triumeq (dolutegravir + abacavir + lamivudine). The STRIIVING study presented 48-week data on switching to Triumeq from various other regimens in people currently on treatment…Read More

AIDS2016: Long-acting injectable two-drug HIV regimen works well as oral “maintenance” treatment

logo_aids2016_sm

People who switched to a new long-acting two-drug injectable HIV regimen after a lead-in period of oral treatment showed equal control of the virus as those who stayed on the oral regimen. The LATTE-2 study presented early data that showed that long acting formulations of the…Read More

AIDS2016: Most study participants were satisfied with a new long-acting injectable HIV regimen

logo_aids2016_sm

A follow-up analysis from LATTE-2 showed that most participants generally favored an injectable HIV regimen to taking daily pills, with many stating that it helped with stigma. An analysis was presented from 39 in-depth interviews of 27 participants (2 of whom were women) and 12 clinicians…Read More

AIDS2016: Once daily dosing for raltegravir (Isentress) may be coming

logo_aids2016_sm

Early study shows that a higher milligram pill of raltegravir taken once a day controls HIV levels as well as its current twice-a-day dosing. The ONCEMRK study presented data on 797 people who were new to treatment and who took one of two different doses of…Read More

AIDS2016: HIV/HCV co-infected persons achieve high cure rates with sofosbuvir/velpatasvir: Results from the ASTRAL-5 Study

logo_aids2016_sm

The new drug combination of sofosbuvir/velpatasvir, brand name Epclusla, received FDA approval on June 28, 2016 for all HCV genotypes as well for those living with cirrhosis. It was not approved for HIV/HCV co-infected persons, however, as results from the study were not yet available at…Read More

AIDS2016: Life expectancy for people living with HIV has increased again with recent analysis

logo_aids2016_sm

The Swiss HIV Cohort Study presented additional data this year showing that life expectancy has increased another 34 years for a person who is on HIV treatment and in care. Data were presented from comparing various life factors that influenced life expectancy in 16,532 HIV-positive people…Read More